Neuropeptide Y antagonists

A compound of the formula

• 15
• Wherein X is NR4R5 where R4 and R5 are selected independently from C1-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C2-C8 alkynyl, C2-C8 alkylalkoxy, alkylaryl, alkylheteroaryl, SO2R7, or SO2NR7R8;
• each optionally substituted with 1-2 substituents independently selected from R6;
• or R4 and R5 are taken together to form a nitrogen containing ring of 3 to 8 atoms, optionally substituted with 1-2 substituents independently selected from R6;
• C5-C8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R6;
• or a heterocyclic ring containing up to two heteroatoms selected from the group consisting of —O—, —NR7—, and —S(O)m— optionally substituted with 1-3 substituents independently selected from R6. Furthermore, when R4 and R5 are taken together to be C3-C8 cycloalkyl, C5-C8 cycloalkenyl, or a heterocyclic ring as described above then said ring system may be further substituted to form an additional 3-8 membered ring optionally containing up to two heteroatoms selected from the group consisting of —O—, —NR7—, and —S(O)m—. Furthermore, R5 may be selected from NR7R8;
• and
• R6 is selected from hydrogen;
• halogen, nitro, cyano, hydroxy, alkylalkoxy, COOH, C1-C6 alkyl;
• C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, aryl, heteroaryl, aryloxy, heteroaryloxy, alkoxy;
• acyloxy, NR7NR8, C1-C4 alkylthio, mono-, di-, or trihaloalkyl;
• and
• R7and R8 are independently selected from H, C1-C6 alkyl;
• C2-C6 alkenyl, alkylalkoxy, C2-C6 alkynyl, aryl, or heteroaryl;
• and may be joined to form a carbocyclic or heterocyclic ring;
• and
• Y is selected from C1-C6alkyl;
• alkoxyalkyl, C2-C6 alkenyl;
• C2-C6alkynyl, alkoxy, aryl, or heteroaryl, or NR4R5 as defined for X;
• and
• R3 is selected from aryl or heteroaryl, optionally substituted with 1-3 substituents chosen from R6;
• m is 0, 1, or 2;
• And with the proviso that Y is not CF3;
• And with the further proviso that when Y is alkyl or alkoxy, X is not NR6(CH2)nNR7R8.